ArticleACS omega2026
pH-Responsive Tamoxifen-Loaded Poly(ε-caprolactone)/Poly(vinylpyrrolidone)/Poly(ethylene oxide) Fibers for Treatment of Breast Cancer: Investigation of Controlled Drug Release Properties.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herein, this study reports the production of fiber mats obtained by electrospinning, produced by mixing tamoxifen (TAM) drug with polycaprolactone (PCL), polyvinylpyrrolidone (PVP), and poly-(ethylene oxide) (PEO), with the aim of eliminating cancer cells through controlled drug release. The fabricated fiber mats were thoroughly characterized by several analytical techniques. FTIR analysis indicated strong intermolecular interactions between polymer molecules of the fiber. XRD analysis revealed that fibers are semicrystalline in nature. Scanning electron microscopy verified the uniform nanofibers with bead-free morphology and the average fiber diameter ranged from 346 to 418 nm with drug loading. An increase in tensile strength (TS) and elongation at break (EAB) values of the fibers was observed after drug loading. TS and EAB was obtained up to 0.35 MPa and 88.69%, which are desired for the application. The release of TAM from the fabricated fibers strongly depended on pH value and the drug was fully released in 100 h at pH 5.5. Moreover, Higuchi, Hixson-Crowell, and Korsmeyer-Peppas kinetics confirmed the controlled release of the drug from the fiber mats via diffusion. After 24, 48, and 72 h, the cell viability rates in L929 cells were determined to be 69.7%, 88.5%, and 63.7%, respectively, while cell viability rates were calculated as 69.9%, 68.9%, and 57.7%, respectively, in MCF-7 cells. Additionally, acridine orange (AO)/ethidium bromide (EB) staining was used to detect apoptosis, and fluorescent staining images revealed apoptotic effects. Taken together, these findings suggested that the produced fiber mats could be a promising candidate for controlled TAM release in breast cancer treatment.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.